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Abstract: Four novel bisquaternary aldoxime cholinesterase reactivators differing in their 
chemical structure were prepared. Afterwards, their biological activity was evaluated for 
their ability to reactivate acetylcholinesterase (AChE; EC 3.1.1.7) and butyryl-
cholinesterase (BuChE; EC 3.1.1.8) inhibited by paraoxon. Their reactivation activity was 
compared with standard reactivators—pralidoxime, obidoxime and HI-6—which are 
clinically used at present. As it resulted, none of the prepared compounds surpassed 
obidoxime, which is considered to be the most potent compound if used for reactivation of 
AChE inhibited by paraoxon. In case of BuChE reactivation, two compounds (K053 and 
K068) achieved similar results as obidoxime. 
Keywords: acetylcholinesterase; butyrylcholinesterase; reactivator; nerve agent; oxime; 
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Introduction 
Acetylcholinesterase (AChE; EC 3.1.1.7) reactivators are a group of drugs originally developed as 
antidotes for the treatment of nerve agent poisonings [1]. They are administered by soldiers using 
autoinjectors in case of need as immediate help if they are intoxicated by nerve agents [2]. With the 
increasing demands on the agricultural production, several kinds of pesticides are being extensively 
used. Among them, organophosphorus pesticides play a very important role [3]. Unfortunately, these 
compounds act biochemically very similarly to nerve agents (e.g., sarin). They inhibit the enzymes 
AChE and butyrylcholinesterase (BuChE; 3.1.1.8) [2,4]. If AChE is considered, its inhibition is a life 
threatening process, because AChE terminates nerve impulses on the synaptic clefts of the nerve 
system [2]. After the inhibition, it cannot degrade the neuromediator acetylcholine (ACh), ACh 
cumulates on the synaptic clefts, it overstimulates receptors and the intoxicated organism can die 
because of cholinergic crisis [2]. 
Standard therapy of such intoxications consists of administration of anticholinergic drugs (mostly 
atropine), AChE reactivators (pralidoxime, obidoxime, HI-6 are clinically used; Figure 1) and 
anticonvulsives (diazepam or avizafone) [5]. The choice of anticholinergics and anticonvulsives is 
relatively resistant to changes. On the contrary, many new derivatives among the group of AChE 
reactivators are described.  
At the end of the 20th century, novel approaches for the pre-treatment of nerve agent intoxications, 
bioscavengers, were investigated. Bioscavengers (cholinesterases, phosphotriesterase, or human 
paraoxonase) could neutralize nerve agents in the blood stream before they reach their physiological 
targets. The most investigated, human serum BuChE (EC 3.1.1.8), can be used successfully with 
relatively high protective potency [6,7]. 
In this study, we have prepared four novel bisquaternary aldoxime cholinesterase reactivators 
(K053, K054, K068 and K071) with the aim of obtaining new more promising oxime candidates which 
could in future replace the clinically used reactivators (Figure 2). Paraoxon (POX) was selected as an 
appropriate organophosphate inhibitor of cholinesterases in our experiments. The newly prepared 
compounds were also tested for their reactivation of BuChE. BuChE reactivation is at present time 
well-investigated to get a so-called “pseudocatalytic scavenger” able to act as prophylaxis or treatment 
of nerve agent poisonings [8-10]. 
Figure 1. Chemical structures of clinically used acetylcholinesterase reactivators. 
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Figure 2. Chemical structures of novel acetylcholinesterase reactivators. 
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Results and Discussion 
All obtained results are summarized in Table 1 and for better visualization also in Figure 3. As 
resulted, obidoxime was the most potent reactivator in treatment of paraoxon-inhibited AChE at both 
concentrations tested (10 µM and 100 µM). Newly prepared oxime K053 together with pralidoxime 
and HI-6 reached comparable results which are considered to be satisfactory for survival of the 
intoxicated organism [2]. All other evaluated oximes were not effective in case of AChE reactivation. 
In case of BuChE reactivation, much more bad results were obtained. This result corresponds with the 
general finding described already earlier, that reactivation of BuChE is very difficult and different to 
that for AChE [11,12]. In this case, obidoxime and two novel oximes (K053 and K068) achieved 
reactivation around 10%. No other oximes (including pralidoxime and HI-6) were able to reactivate 
sufficiently the POX-inhibited BuChE. 
Table 1. Potency of the tested oximes to reactivate POX- inhibited human erythrocyte 
AChE and plasma BuChE at concentrations 100 µM and 10 µM. (%, mean value of three 
independent determinations, time of inhibition by paraoxon 120 min; time of reactivation 
by AChE reactivators - 10 min; pH 7.4; temperature 25 ºC). 
  Reactivation (%) 
  AChE BuChE 
Concentration 100 µM 10 µM 100 µM 10 µM 
Reactivator  Mean S.D. Mean S.D. Mean S.D. Mean S.D. 
Pralidoxime6  18.0 0.7 1.3 0.7 5.5 0.1 1.0 0.2 
Obidoxime6 96.9 0.7 59.4 0.7 9.9 0.3 2.2 0.3 
HI-6 6 16.1 0 3.9 0.7 2.3 0.2 0.8 0.4 
K053 21.4 1.4 7.3 0.8 10.7 0.6 1.4 0 
K054 0 0 0.4 0 0.2 0 0.2 0 
K068 5.4 1.0 1.5 0.4 10.4 0 1.7 0 
K071 0 0 0 0 0 0 0 0 
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Figure 3. Reactivation of paraoxon-inhibited AChE and BuChE by the novel bisquaternary 
aldoxime reactivators. 
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If the obtained results are compared, the new AChE reactivators are not better than the clinically 
used ones, so that their further investigation cannot be recommended. Due to this, novel structurally 
different oximes derived from clinically used ones (especially from obidoxime) should be designed 
and tested for their reactivation potency against POX. On the contrary, if BuChE reactivation is 
considered, only two oximes (K053 and K068) achieved 10% reactivation. Due to this, if novel BuChE 
reactivators are to be designed in the future, the results of this study could be used as first 
approximation to the desired structure with higher BuChE reactivation potency. 
Experimental 
General 
All chemicals used in this study were of reagent grade. They were obtained from commercial 
sources (Sigma-Aldrich, Czech Republic). Paraoxon (POX; O,O-diethyl-O-4-nitrophenylphosphate, 
95% purity) was purchased from Dr. Ehrenstorfer (Augsburg, Germany). 1H- and 13C-NMR spectra 
were recorded at 300 and 75 MHz, respectively, on a Varian Mercury 300 spectrometer, using D2O as 
solvent. All experiments were carried out in compliance with the current law of Czech Republic. 
Synthesis 
All newly prepared reactivators were prepared using the standard synthetic approach described 
previously by Musilek et al. [13,14]. As can be clearly seen from the reactivators´ structure, in the case 
of asymmetric reactivators there is the need to prepare them through the monoquaternary intermediate. 
To obtain the monoquaternary compound, there is a need of mild conditions to prevent a creation of 
symmetric bisquaternary compound (Scheme 1). NMR data together with melting points and yields of 
prepared compounds are listed below: 
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Scheme 1. General scheme of the synthesis of novel acetylcholinesterase reactivators. 
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trans-2,4’-Bis[(hydroxyimino)methyl]-1,1’-(but-2-ene-1,4-diyl)bispyridinium dibromide (K053): yield 
68%; m.p. 194-196 °C; 1H-NMR δ: 5.52 (d, 2H, J = 4.5 Hz, CH2), 5.89 (d, 2H, J = 8 Hz, CH2), 6.03 
(dt, 1H, J = 16, 4.5 Hz, CH=), 6.34 (dt, 1H, J = 16, 8 Hz, CH=), 8.07 (t, 1H, J = 6 Hz, arom H-5), 8.21 
(d, 1H, J = 6 Hz, arom H-3), 8.24 (d, 2H, J = 6 Hz, arom H-3’, H-5’), 8.38 (s, 1H, CH=N), 8.61 (t, 1H, 
J = 6 Hz, arom H-4), 8.63 (s, 1H, CH=N), 8.85 (d, 1H, J = 6 Hz, arom H-6), 8.87 (d, 2H, J = 6 Hz, 
arom H-2’, H-6’). The signals of =NOH disappeared in deuterated solvent; 13C-NMR δ: 48.37 (CH2), 
62.23 (CH2), 126.94 (CH=), 126.96 (CH=), 127.02 (CH-3’,5’), 129.90 (CH-3), 132.85 (CH-5), 146.95 
(CH-2’,6’), 146.99 (CH-6), 148.18 (C-4’), 148.21 (CH-4), 148.74 (CH=N), 151.41 (CH=N), 157.37 
(C-2). 
 
trans-3,4-Dicarbamoyl-2’-(hydroxyimino)methyl-1,1’-(but-2-ene-1,4-diyl)bispyridinium dibromide 
(K054): yield 55%; m.p. 209-211 °C; 1H-NMR δ: 5.40 (d, 2H, J = 7 Hz, CH2), 5.54 (d, 2H, J = 5 Hz, 
CH2), 6.04 (dt, 1H, J = 16, 7 Hz, CH=), 6.42 (dt, 1H, J = 16, 5 Hz, CH=), 8.09 (t, 1H, J = 6 Hz, arom 
H-5’), 8.34 (d, 1H, J = 6 Hz, arom H-3’), 8.43 (d, 1H, J = 7 Hz, arom H-5), 8.59 (t, 1H, J = 6 Hz, arom 
H-4’), 8.64 (s, 1H, CH=N), 8.86 (d, 1H, J = 6 Hz, arom H-6’), 9.11 (d, 1H, J = 7 Hz, arom H-6), 9.25 
(s, 1H, arom H-2). The signals of CONH2 and =NOH disappeared in deuterated solvent; 13C-NMR δ:  
48.48 (CH2), 61.25 (CH2), 127.51 (CH=), 129.08 (CH=), 129.30 (CH-5), 129.91 (CH-3’), 130.27 (CH-
5’), 135.86 (C-3), 144.12 (CH-6), 146.76 (CH-6’), 148.37 (CH-4’), 148.76 (CH-2), 149.88 (CH=N), 
152.04 (C-4), 157.32 (C-2’), 167.90 (CONH2), 169.49 (CONH2). 
 
trans-2,2’-Bis[(hydroxyimino)methyl]-1,1’-(but-2-ene-1,4-diyl)bispyridinium dibromide (K068): yield 
60%; m.p. 196-199 °C; 1H-NMR δ: 5.28 (d, 4H, J = 5 Hz, 2 x CH2), 6.06 (t, 2H, J = 5 Hz, 2 x CH=), 
8.08 (dt, 2H, J = 8, 1.5 Hz, 2 x arom H-5), 8.38 (dd, 2H, J = 8, 1.5 Hz, 2 x arom H-3), 8.60 (dt, 2H,  
J = 8, 1.5 Hz, 2 x arom H-4), 8.78 (s, 2H, 2 x CH=N), 8.87 (dd, 2H, J = 8, 1.5 Hz, 2 x arom H-6). The 
signal of =NOH disappeared in deuterated solvent; 13C-NMR δ: 48.53 (CH2), 127.45 (CH=), 129.80 
(CH-3), 130.53 (CH-5), 145.01 (CH-6), 148.57 (CH-4), 148.74 (CH=N), 157.31 (C-2). 
 
trans-4’-tert-Butyl-2-(hydroxyimino)methyl-1,1’-(but-2-ene-1,4-diyl)bispyridinium dibromide (K071): 
yield 47%; m.p. > 300 °C; 1H-NMR δ: 1.25 (s, 9H, 3 x CH3), 5.22 (d, 2H, J = 5 Hz, CH2), 5.84 (d, 2H, 
J = 8 Hz, CH2), 6.04 (dm, 1H, J = 16 Hz, CH=), 6.32 (dm, 1H, J = 16 Hz, CH=), 8.02-9.25 (m, 8H, 
arom), 8.64 (s, 1H, CH=N). The signal of =NOH disappeared in deuterated solvent; 13C-NMR δ: 31.55 
(CH3), 38.45 (C), 48.38 (CH2), 64.37 (CH2), 126.61 (CH-3’,5’), 127.47 (CH=), 127.54 (CH=), 128.30 
(CH-3), 129.84 (CH-5), 142.96 (CH-2’,6’), 146.05 (CH-6), 146.69 (CH-4), 148.70 (CH=N), 157.94 
(C-2), 166.88 (C-4’). 
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Biochemical  
Purity of novel compounds was checked once again using TLC technique and HPLC technique 
immediately prior the experiment [15,16]. Reactivation activity of the synthesized reactivators was 
tested using our in vitro reactivation test [9]. A short description of this method is summarized here: 
human erythrocyte AChE or plasma BuChE were inhibited by solution of paraoxon to 5% of their 
original activity. Time of enzyme inhibition with paraoxon (2 hours, corresponding to 7 × T1/2) was 
calculated from experimentally determined half life (T1/2) of reaction between enzyme and paraoxon. 
Then, the inhibited enzyme was incubated for 10 min with a solution of reactivator at concentration 
10-4 M and 10-5 M. Activity of AChE (BuChE) was measured spectrophotometrically by modified 
method according to Ellman with acetylthiocholine (butyrylthiocholine) as substrate [17]. The 
reactivation potency was calculated from the formula:  
%R = (1-(a0-ar)/(a0-ai))×100 
where %R is percent of reactivation, a0 is activity of intact enzyme, ai is activity of inhibited enzyme 
and ar is activity of reactivated enzyme minus oximolysis and spontaneous hydrolysis. Each 
measurement was repeated three times and was conducted under standard laboratory temperature  
(25 ºC). Calculations were performed using software GraphPad Prism version 4.00 for Windows, 
GraphPad Software, San Diego California USA (www.graphpad.com).  
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